Hillary L. Sturgis

Crystal Structure of Human AKT1 with an Allosteric Inhibitor Reveals a New Mode of Kinase Inhibition

Wen‐I Wu, W.C. Voegtli, Hillary L. Sturgis et al. · PLoS ONE · 2010 · 326 citations · Full text

Life Sciences, Molecular Biology, Pharmacology +14

Pyrazolopyridine Inhibitors of B-Raf^V600E. Part 1: The Development of Selective, Orally Bioavailable, and Efficacious Inhibitors

Steve Wenglowsky, Li Ren, Kateri A. Ahrendt et al. · ACS Medicinal Chemistry Letters · 2011 · 66 citations · Full text

Medicine, Oncology, Pharmacology +15

Pyrazolopyridine inhibitors of B-RafV600E. Part 2: Structure–activity relationships

Steve Wenglowsky, Kateri A. Ahrendt, Alex J. Buckmelter et al. · Bioorganic & Medicinal Chemistry Letters · 2011 · 56 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +13

Pyrazolopyridine inhibitors of B-RafV600E. Part 4: Rational design and kinase selectivity profile of cell potent type II inhibitors

Steve Wenglowsky, David Moreno‐Mateos, Ellen R. Laird et al. · Bioorganic & Medicinal Chemistry Letters · 2012 · 29 citations · Full text

Pharmacy, Medicinal Chemistry, Oncology +16

Highly potent and selective 3-N-methylquinazoline-4(3H)-one based inhibitors of B-RafV600E kinase

Steve Wenglowsky, Li Ren, Jonas Grina et al. · Bioorganic & Medicinal Chemistry Letters · 2014 · 19 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +11